Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Novo Nordisk made two very different kinds of news on the same day, and together they tell you exactly where this company is right now. The subscription pricing program for Wegovy is an aggressive defensive move: Novo has lost significant market share to Lilly (60% to 39% in branded GLP-1s, per CNBC) and is now using telehealth distribution and predictable pricing to lock in self-pay patients before orforglipron arrives in 8 days. At the same time, Novo confirmed 400 layoffs at the Bloomington manufacturing site it inherited from the Catalent acquisition, part of 9,000 global cuts designed to save $1.25B annually. One hand is building new commercial infrastructure. The other is trimming legacy costs. That's what a company looks like when it's simultaneously fighting for market share and restructuring operations under a new CEO. 👉 Read Full Analysis

Novo Launches Wegovy Subscription Pricing Through Telehealth Partners NVO

What Happened: Novo Nordisk launched a multi-month subscription program for Wegovy on March 31, available through telehealth partners Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to follow. Self-pay patients can choose 3, 6, or 12-month subscription plans with predictable monthly pricing. NVO shares rose 4.1% on the announcement.

The Pricing: Wegovy injection subscriptions run $329/month (3-month plan), $299/month (6-month plan), or $249/month (12-month plan), representing savings of up to $1,200 per year versus standard self-pay pricing. Wegovy pill subscriptions range from $289/month (3-month) to $249/month (12-month), saving up to $600 per year. The lower pill doses (1.5mg and 4mg) remain available at $149/month outside the subscription model.

Executive Impact: This is Novo playing defense. Lilly controls roughly 60% of the U.S. branded GLP-1 market versus Novo's approximately 39%. The Wegovy pill has been reaching mostly new GLP-1 patients since its January launch, and Novo needs to capture and retain as many of those patients as possible before orforglipron arrives. The subscription model is designed to solve two problems at once: price predictability (which patients cite as a top barrier) and adherence (studies show approximately 65% of obesity patients discontinue GLP-1 treatment within one year). Reuters noted that Novo has already cut Wegovy's self-pay price from $499 to $349 in November, making this the second major pricing move in five months. The competitive pressure is real.

Novo Cuts 400 Jobs at Embattled Bloomington Manufacturing Site NVO

What Happened: Novo Nordisk confirmed it will cut approximately 400 positions at its Bloomington, Indiana manufacturing site, effective early May. The site, formerly operated by Catalent, will retain approximately 1,400 employees after the reduction. The cuts represent roughly 22% of the facility's workforce.

The Backstory: This site has had a troubled history. Catalent's ownership (2017 to late 2024) was marked by repeated layoffs, FDA scrutiny, and allegations of mismanagement. Novo Holdings acquired the plant through the Catalent buyout in December 2024, primarily to secure Wegovy manufacturing capacity during peak demand. An FDA inspection flagged issues at the facility in mid-2025, and Novo responded to the resulting warning letter in December. The Bloomington cuts are part of Novo's broader restructuring under CEO Maziar Mike Doustdar, who announced 9,000 global job cuts in September 2025 targeting $1.25B in annual savings.

Executive Impact: Despite the layoffs, Novo says it continues to invest in the site and views it as a critical part of its U.S. manufacturing network. BioSpace reported a notable counterpoint: Scholar Rock refiled its apitegromab NDA this week including the Bloomington facility, signaling that the FDA remediation has progressed enough for a client to trust the site with a regulatory filing. That's a meaningful data point about the facility's operational trajectory even as headcount shrinks.

Medtronic Expands Stealth Axis Surgical Robot into Cranial and ENT MDT

What Happened: Medtronic received FDA 510(k) clearance to expand its Stealth Axis surgical navigation and robotics platform into cranial and ear, nose, and throat (ENT) procedures. This follows the system's initial clearance for spine surgery in February 2026.

The Platform: Stealth Axis integrates surgical planning, real-time navigation, and a floor-mounted robotic arm into a single workflow. The system is powered by an AI-driven architecture that provides intraoperative visualization before, during, and after procedures. The expansion from spine into cranial and ENT positions it as a multi-specialty surgical robotics platform.

Executive Impact: Medtronic is targeting a piece of the $15 billion cranial and spinal technologies market with Stealth Axis. The multi-specialty clearance strategy is important: rather than building separate systems for each surgical discipline, Medtronic is creating a unified platform that hospitals can deploy across departments. That is a fundamentally different commercial approach than single-specialty competitors. Heart Rhythm 2026 in April is expected to be a key showcase for the broader Medtronic robotics portfolio.

👉 Read Full Analysis

The BioMed Nexus Industry Directory Is Officially Live: We have been building something quietly for the past several months, and it is finally ready. The BioMed Nexus Industry Directory is now the one of the most comprehensive categorized database of companies across biotech, pharma, and life sciences, with 2,100+ companies listed across 14 live directories.

Whether you are sourcing CROs, mapping the AI drug discovery landscape, evaluating CDMOs, or looking for regulatory counsel, it is all in one place. Every directory is searchable, categorized, and updated weekly by our editorial team.

👉 Browse the full directory here

Note: Companies can claim a free listing or upgrade to a featured profile. If you want your company visible to our full 86,000+ biotech professionals, reply to this email to learn about our Data Partner program.

Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here